ClinicalTrials.gg
Not yet recruitingNCT06306560Updated Mar 12, 2024

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

A Phase 2 interventional study of adebrelimab and famitinib in Extensive-stage Small-cell Lung Cancer, sponsored by Harbin Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Harbin Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing adebrelimab in Small Cell Lung Carcinoma — 21 open to participants now, 23 under way, 2 of them phase 3. adebrelimab · Small Cell Lung Carcinoma.

Planned enrollment
15th of 25
40 · median 47
Started
2024
with 6 others
Phase 2
16 of 25
14 open now
Primary completion
2027-03
later than 11 of 22 live
Registered
8th of 25
by date
Lead sponsor
1 of 25
Harbin Medical University

Among the 25 studies testing adebrelimab in Small Cell Lung Carcinoma, this one is the 15th largest by planned enrollment, is one of 7 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 11 of the 22 other live ones, and was the 8th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

21 of the 25 studies testing adebrelimab in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing adebrelimab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.

Read the detailed description

This study plans to recruit 40 patients with extensive-stage small cell lung disease who have not received treatment, observe and evaluate the effectiveness and safety of adebrelimab combined with famitinib and chemotherapy.

03

Conditions studied

  • Extensive-stage Small-cell Lung Cancer

Keywords

  • Adebrelimab
  • Famitinib
  • Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-80 years old, male or female
  2. Patients with confirmed extensive stage small cell lung cancer (according to the Veterans Administration Lung Study Group, VALG staging)
  3. Never received prior systemic therapy for extensive stage small cell lung cancer
  4. Have a measurable tumour target lesion (meeting 1.1 criteria)
  5. Expected survival > 3 months
  6. PS: 0-1 points
  7. Normal function of major organs
  8. Women of must undergo a negative pregnancy test (βHCG) prior to initiation of treatment, and women of childbearing potential and men (who are sexually active with women of childbearing potential) must agree to use effective uninterruptedly for the duration of the treatment period and for 6 months after the administration of the last therapeutic dose
  9. Patients voluntarily enrolled in this study by signing an form

Exclusion criteria

Exclusion Criteria:

  1. Previous or concurrent other malignant tumours within 5 years, except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, superficial or non-invasive bladder cancer
  2. Active tuberculosis infection, or a history of previous tuberculosis infection
  3. Uncontrolled, symptomatic that are not effectively controlled or a history of psychiatric illness that cannot be easily controlled or severe intellectual or cognitive dysfunction
  4. Subjects with active, known or suspected disease, hypothyroidism requiring only hormone replacement therapy, skin disorders not requiring systemic therapy (e.g., vitiligo, psoriasis, or alopecia areata) may be eligible for enrolment
  5. Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage
  6. Subjects with the presence of any severe and/or uncontrolled disease
  7. Imaging showing tumour invasion of large vessels or poor demarcation from large vessels
  8. Susceptibility to bleeding, risk of hemoptysis, and history of significant coagulation disorders
  9. History of psychotropic substance abuse, alcoholism or drug addiction
  10. Active hepatitis ( reference: HBsAg positive with HBV DNA test value exceeding the value reference HCV antibody positive with HCV viral titre test value exceeding the upper limit of normal value)
  11. (HIV, HIV 1/2 antibody) positive
  12. Patients who are unable to comply with the trial protocol or who are unable to cooperate with follow-up visits
  13. Patients who, in the opinion of the investigator, should not be enrolled in the trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Immuno-cherapy for extensive small cell lung cancer

    Adebrelimab in combination with famitinib and chemotherapy

    Drug: adebrelimab · Drug: famitinib · Drug: chemotherapy

Interventions

  • adebrelimab IV

    Also known as: SHR-1316

  • famitinib PO

    Also known as: SHR1020

  • Drugchemotherapy

    chemotherapy IV

    Also known as: cisplatin/carboplatin and etoposide

06

What researchers measure

Primary outcomes

  1. 6-month progression-free survival

    Proportion of disease progression or death from randomization to 6 months of treatment.

    Time frame: up to 6 months

Secondary outcomes

  1. 12-month progression-free survival

    Proportion of disease progression or death from randomization to 12 months of treatment.

    Time frame: up to 12 months

  2. Objective Response Rate

    Determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment.

    Time frame: up to 24 months

  3. Disease control rate

    Disease Control Rate, determined using RECIST v1.1 criteria.

    Time frame: up to 24 months

  4. Overall Survival

    Defined as the time from randomization to death from any cause.

    Time frame: up to 24 months

  5. AEs

    Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.

    Time frame: up to 24 months

  6. QoL

    Defined as time from randomization to deterioration on each of the EORTC QLQ-C30 symptom subscales

    Time frame: up to 24 months

  7. Progression-Free-Survival

    Defined as the time from randomization to the first occurrence of disease progression with use of RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2027, 36 months later.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 36 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 12, 2024
StartEst.
Mar 15, 2024
Primary completionEst.
Mar 15, 2027
CompletionEst.
Apr 15, 2027
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06306560
Lead sponsor
Harbin Medical University
Responsible party
Yanbin Zhao (MD, Harbin Medical University) — Principal investigator
First posted
Mar 12, 2024
Start date
Mar 15, 2024 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Mar 12, 2024

Study contacts

Yanbin Zhao, MD
Contact
zhaoyanbin1978@sina.com
13904811741
Yanbin Zhao, MD
principal investigator · Harbin Medical University Cancer Hosptital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Famitinib

Start the discussion